Stock listing
NASDAQ:AKTX Akari Therapeutics PLC Stock
Follow Akari Therapeutics PLC into a list and get an email when it puts out news.
Share price · NASDAQ:AKTX
$7.18 USD +0.53 (+8.0%)
Close on Nov 20, 2026
- Day range
- $6.20 – $7.44 USDNov 20, 2026
- Volume
- 15,265 sharesNov 20, 2026
- Market cap
- $16.41M USDAt the close on Nov 20, 2026 · price × 2.29M shares outstanding
- 52-week range
- $3.02 – $29.32 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $546,691 USDMedian day 42,293 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AKTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.18 | +0.53 | +8.0% | $7.00 | $7.44 | $6.20 | 15,265 | |
| $6.65 | +0.95 | +16.7% | $5.87 | $7.25 | $5.71 | 9,795 | |
| $5.70 | -0.81 | -12.4% | $6.11 | $6.257 | $5.70 | 11,457 | |
| $6.51 | -0.29 | -4.3% | $7.045 | $7.045 | $6.35 | 28,032 | |
| $6.80 | +0.29 | +4.5% | $6.52 | $7.547 | $6.52 | 21,412 | |
| $6.51 | -0.94 | -12.6% | $7.67 | $7.69 | $6.51 | 13,956 | |
| $7.45 | +0.32 | +4.5% | $7.46 | $7.65 | $7.156 | 22,353 | |
| $7.13 | -0.53 | -6.9% | $7.46 | $7.58 | $6.94 | 26,989 | |
| $7.66 | +0.29 | +3.9% | $7.61 | $7.89 | $7.33 | 41,712 | |
| $7.37 | -0.38 | -4.9% | $7.77 | $8.375 | $7.27 | 53,243 | |
| $7.75 | -1.54 | -16.6% | $8.80 | $9.025 | $7.60 | 31,878 | |
| $9.29 | +1.14 | +14.0% | $8.13 | $9.38 | $8.13 | 87,902 | |
| $8.15 | +0.31 | +4.0% | $8.39 | $8.61 | $7.99 | 63,279 | |
| $7.84 | -0.40 | -4.9% | $8.40 | $8.40 | $7.57 | 11,862 | |
| $8.24 | +0.24 | +3.0% | $8.50 | $8.95 | $8.071 | 45,653 | |
| $8.00 | -1.20 | -13.0% | $9.13 | $9.83 | $8.00 | 97,012 | |
| $9.20 | +0.62 | +7.2% | $8.665 | $9.325 | $8.29 | 42,293 | |
| $8.58 | +0.95 | +12.5% | $7.94 | $8.64 | $7.94 | 38,455 | |
| $7.63 | -0.595 | -7.2% | $7.64 | $8.45 | $7.63 | 67,835 | |
| $8.225 | +0.125 | +1.5% | $8.00 | $8.45 | $7.84 | 14,391 | |
| $8.10 | -0.66 | -7.5% | $8.69 | $9.115 | $7.58 | 20,885 | |
| $8.76 | -0.53 | -5.7% | $9.39 | $9.939 | $8.76 | 30,596 | |
| $9.29 | -0.60 | -6.1% | $9.15 | $9.725 | $9.15 | 34,615 | |
| $9.89 | +1.71 | +20.9% | $9.01 | $10.00 | $8.52 | 78,982 | |
| $8.18 | -0.66 | -7.5% | $8.72 | $8.72 | $8.025 | 21,689 | |
| $8.84 | +1.56 | +21.4% | $7.87 | $8.89 | $7.00 | 55,708 | |
| $7.28 | -0.62 | -7.8% | $8.10 | $8.10 | $7.19 | 34,943 | |
| $7.90 | -0.64 | -7.5% | $8.33 | $8.70 | $7.90 | 18,500 | |
| $8.54 | -0.23 | -2.6% | $8.70 | $9.05 | $8.34 | 112,400 | |
| $8.77 | +0.64 | +7.9% | $8.51 | $8.97 | $8.20 | 76,400 | |
| $8.13 | -0.495 | -5.7% | $8.61 | $8.73 | $8.13 | 61,900 | |
| $8.625 | +0.235 | +2.8% | $8.46 | $8.625 | $8.05 | 32,400 | |
| $8.39 | -0.55 | -6.2% | $8.96 | $8.96 | $8.13 | 19,800 | |
| $8.94 | +0.22 | +2.5% | $8.84 | $9.39 | $8.53 | 9,600 | |
| $8.72 | -0.12 | -1.4% | $9.01 | $9.14 | $8.26 | 15,300 | |
| $8.84 | -0.46 | -4.9% | $9.35 | $10.00 | $8.55 | 28,600 | |
| $9.30 | -0.42 | -4.3% | $9.58 | $10.05 | $8.80 | 47,000 | |
| $9.72 | -0.09 | -0.9% | $9.83 | $10.75 | $9.55 | 50,700 | |
| $9.81 | +0.055 | +0.6% | $9.99 | $10.98 | $9.69 | 82,000 | |
| $9.755 | -0.305 | -3.0% | $10.25 | $10.25 | $9.30 | 71,500 | |
| $10.06 | +0.40 | +4.1% | $9.90 | $10.10 | $9.565 | 47,400 | |
| $9.66 | -0.39 | -3.9% | $10.42 | $10.42 | $9.32 | 86,400 | |
| $10.05 | +0.67 | +7.1% | $9.236 | $10.10 | $8.53 | 78,500 | |
| $9.38 | +0.22 | +2.4% | $9.52 | $9.81 | $9.07 | 18,700 | |
| $9.16 | -0.715 | -7.2% | $9.63 | $10.13 | $9.16 | 63,700 | |
| $9.875 | -0.245 | -2.4% | $10.26 | $10.74 | $9.39 | 126,400 | |
| $10.12 | -0.13 | -1.3% | $11.00 | $11.00 | $9.78 | 16,400 | |
| $10.25 | -0.79 | -7.2% | $11.05 | $11.05 | $10.00 | 27,600 | |
| $11.04 | -0.26 | -2.3% | $11.43 | $11.61 | $10.68 | 40,000 | |
| $11.30 | +0.42 | +3.9% | $10.51 | $11.50 | $10.51 | 134,100 | |
| $10.88 | +0.31 | +2.9% | $10.63 | $11.07 | $10.07 | 166,000 | |
| $10.57 | -0.39 | -3.6% | $10.89 | $12.15 | $10.02 | 131,100 | |
| $10.96 | -0.51 | -4.4% | $11.32 | $12.04 | $10.75 | 128,500 | |
| $11.47 | +0.63 | +5.8% | $10.41 | $11.82 | $10.17 | 108,600 | |
| $10.84 | +0.69 | +6.8% | $10.00 | $11.40 | $9.65 | 61,900 | |
| $10.15 | -0.22 | -2.1% | $10.09 | $10.40 | $9.60 | 46,500 | |
| $10.37 | -0.06 | -0.6% | $10.44 | $10.50 | $9.44 | 174,800 | |
| $10.43 | -0.27 | -2.5% | $10.62 | $11.40 | $9.75 | 81,400 | |
| $10.70 | +1.69 | +18.8% | $8.93 | $11.08 | $8.80 | 168,400 | |
| $9.01 | -0.09 | -1.0% | $9.60 | $9.60 | $8.75 | 54,000 | |
| $9.10 | +1.23 | +15.6% | $8.10 | $9.96 | $7.95 | 254,600 | |
| $7.87 | +0.40 | +5.4% | $7.97 | $8.10 | $7.69 | 30,400 | |
| $7.47 | -0.38 | -4.8% | $8.00 | $8.06 | $7.355 | 41,400 | |
| $7.85 | +0.06 | +0.8% | $8.095 | $8.10 | $7.70 | 11,000 | |
| $7.79 | -0.11 | -1.4% | $8.10 | $8.10 | $7.69 | 16,500 |
Splits
3 splits since 2015 · NASDAQ:AKTX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-40 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:AKTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 29 slides
Latest news
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
Nov 12, 2026
Closed $6.80 (+4.5%) on Nov 13, 2026
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
Nov 11, 2026
Closed $7.45 (+4.5%) on Nov 11, 2026
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
Oct 30, 2026
Closed $8.24 (+3.0%) on Oct 30, 2026
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
Oct 15, 2026
Closed $8.84 (+21.4%) on Oct 15, 2026
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Apr 6, 2026
Closed $3.54 (-20.8%) on Apr 6, 2026
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Dec 23, 2025
Closed $9.80 (-7.2%) on Dec 23, 2025
Akari Therapeutics PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in the last 12 months · 6 in all · newest Nov 12, 2026 · oldest 2025
- Decks
- 32 decks · latest November 2026
Valuation
Price/book 0.9× against a median of 1.6×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $10.66M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.49
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.74M | US$15.65M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.09M | US$10.40M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Median of the others | US$16.10M | US$11.39M | 3.7× | −0.1× | 1.6× | −213.8% | 0.0× | 0.97 |
Forecasts
2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 25.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -9.05 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Abizer Gaslightwala | Director, President and CEO |
| Kameel D. Farag | Interim Chief Financial Officer |
| Satyajit Mitra | Executive Director, Head of Oncology |
| Vatnak Vat-Ho | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Hoyoung Huh | Chairman |
| Abizer Gaslightwala | Director, President and CEO |
| Ray Prudo | Director |
| Robert Bazemore | Director |
| Samir R. Patel | Director |
| Sandip I. Patel | Director |
| Satyajit Mitra | Executive Director, Head of Oncology |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +4.5% |
| Q2 2026 | Aug 13, 2026 · After close | +7.7% |
| Q1 2026 | May 19, 2026 · After close | −8.3% |
| Q3 2025 | Nov 13, 2025 · After close | +1.7% |
| Q2 2025 | Aug 13, 2025 · After close | −1.3% |
| Q1 2025 | Apr 15, 2025 | −1.2% |
| Q3 2024 | Dec 6, 2024 | −7.9% |
| Q2 2024 | Sep 30, 2024 · Before open | +0.3% |
| Q1 2024 | May 15, 2024 · After close | +1.4% |
| Q3 2023 | Oct 12, 2023 · Before open | −2.8% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Sep 29, 2023 · Before open | −3.2% |
| Q1 2023 | May 1, 2023 · Before open | +2.2% |
| Q4 2022 | Mar 30, 2023 · Before open | −16.2% |
| Q3 2022 | Dec 30, 2022 · Before open | +6.8% |
| Q2 2022 | Sep 27, 2022 · After close | +7.7% |
| Q1 2022 | May 16, 2022 · Before open | −2.7% |
| Quarter to Sep 30, 2021 | Dec 3, 2021 · Before open | −2.2% |
| Q2 2021 | Sep 22, 2021 · After close | −1.2% |
| Quarter to Mar 31, 2021 | Jun 29, 2021 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 29 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 30 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 30 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 30 slides | August 2026 |
| Investor Presentation (June 2026) | Investor deck | 27 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 28 slides | May 2026 |
| Investor Presentation (February 2026) | Investor deck | 24 slides | February 2026 |
| Investor Presentation (December 2025) | Investor deck | 25 slides | December 2025 |
| Investor Presentation (October 2025) | Investor deck | 20 slides | October 2025 |
| Investor Presentation (September 2025) | Investor deck | 22 slides | September 2025 |
All 32 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 14.0K | 4.00K | 3.71K | 4.13K | 8.91K | 19.2K | 35.8K | 0 | 39.8K | |
| Gross profit | -14.0K | -4.00K | -3.71K | -4.13K | -8.91K | -19.2K | -35.8K | 0 | -39.8K | |
| Research and development | 2.81M | 6.98M | 5.45M | 9.56M | 9.13M | 8.82M | 8.74M | 11.8M | 23.3M | 17.3M |
| Selling, general and administrative | 9.28M | 9.66M | 11.4M | 13.5M | 8.08M | 9.16M | 8.22M | 11.7M | 11.8M | 9.94M |
| Operating income | -17.3M | -21.6M | -16.8M | -23.1M | -17.2M | -18.0M | -17.0M | -20.8M | -37.8M | -27.2M |
| Depreciation and amortization | 0 | 14.0K | 4.00K | 4.00K | 4.13K | 8.91K | 19.2K | 35.8K | 42.4K | 39.9K |
| EBITDA | -17.3M | -21.6M | -16.8M | -23.1M | -17.2M | -18.0M | -16.9M | -20.7M | -37.7M | -27.2M |
| Interest expense | 100.0K | 244.0K | 0 | 5.34M | 210.1K | 205.0K | 267.0K | 82.0K | 0 | 0 |
| Income before tax | -18.3M | -19.8M | -10.0M | -17.7K | -17.4M | -17.1M | -16.8M | -20.5M | -35.4M | -18.1M |
| Income tax | -1.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -17.3M | -19.8M | -10.0M | -17.7M | -17.4M | -17.1M | -16.8M | -20.5M | -35.4M | -18.1M |
| Earnings per share, basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 |
| Earnings per share, diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.20M | 0 | 3.85M | 13.3M | 9.36M | 14.1M | 5.73M | 5.45M | 28.1M | 34.1M |
| Short-term investments | 0 | 10.0M | ||||||||
| Receivables | 201.0K | 2.95M | 3.51M | 4.54M | 10.4M | |||||
| Inventory | -2.49M | -521.9K | -1.03M | -2.01M | ||||||
| Current assets | 5.46M | 2.95M | 4.34M | 13.8M | 11.6M | 14.6M | 6.44M | 7.45M | 28.8M | 45.6M |
| Property, plant and equipment | 0 | 0 | 0 | 5.01K | 20.4K | 55.9K | 58.4K | |||
| Goodwill | 8.43M | 8.43M | ||||||||
| Total assets | 47.9M | 50.6M | 4.36M | 13.8M | 11.6M | 14.6M | 6.48M | 8.03M | 29.1M | 45.9M |
| Accounts payable | 8.77M | 12.4M | 1.67M | 947.0K | 1.79M | 3.38M | 1.23M | 1.59M | 1.97M | 2.21M |
| Current liabilities | 12.4M | 19.9M | 4.58M | 12.0M | 6.09M | 5.22M | 5.46M | 4.92M | 11.8M | 11.7M |
| Total debt | 754.0K | 3.26M | ||||||||
| Total liabilities | 19.6M | 28.3M | 4.58M | 12.0M | 6.09M | 5.22M | 6.47M | 4.92M | 11.9M | 11.8M |
| Shareholders' equity | 28.3M | 22.2M | -229.0K | 1.79M | 5.55M | 9.38M | 7.60K | 4.37M | 22.2M | 34.1M |
| Shares outstanding | 90.5B | 53.2B | 13.2B | 7.44B | 4.76B | 3.85B | 2.25B | 312.0K | 1.53B | 1.18B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10.6M | -12.6M | -16.4M | -21.5M | -18.8M | -17.0M | -12.9M | -22.8M | -31.6M | -24.6M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -36.9K | -54.8K |
| Free cash flow | -10.6M | -12.6M | -16.4M | -21.5M | -18.8M | -17.0M | -12.9M | -22.8M | -31.6M | -24.7M |
| Cash from investing | 382.0K | 0 | 0 | 9.99M | -10.1M | |||||
| Cash from financing | 13.2M | 11.0M | 7.02M | 25.3M | 14.3M | 25.1M | 12.6M | 500.0K | 15.7M | 0 |
| Share buybacks | 12.6M | 306.2K | 17.4M | 17.4M | ||||||
| Change in cash | 2.60M | -1.19M | -9.40M | 3.89M | -4.69M | 8.32M | -236.3K | -22.3M | -5.99M | -34.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Oct 30, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Oct 1, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jul 14, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jul 10, 2026 | Offer document | SEC |
| S-3/A · Registration statement, amended | Jul 8, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 8, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 2, 2026 | Meeting outcome | SEC |
| S-3 · Registration statement | Jul 2, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2026 | Material contract | SEC |
| S-1/A · Registration statement, amended | Jun 26, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 8, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jun 4, 2026 | Meeting notice | SEC |
| D | Jun 3, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | May 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 22, 2026 | Material contract | SEC |
| RW · Request to withdraw a registration | May 21, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 19, 2026 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 18, 2026 | Explanation request | SEC |
| S-1 · Registration statement | May 8, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 16, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 10, 2026 | Offer document | SEC |
| DRS · Draft registration statement | Apr 2, 2026 | Offer document | SEC |
| F-6/A | Mar 31, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 4, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 2, 2026 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Feb 3, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 27, 2026 | Other filings | SEC |
| S-1 · Registration statement | Jan 23, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Jan 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 17, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 17, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 5, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 1, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 17, 2025 | Meeting notice | SEC |
| S-1 · Registration statement | Nov 17, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Nov 7, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2025 | Insider trade | SEC |
| D | Oct 24, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 23, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 16, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 16, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 15, 2025 | Current report | SEC |
| 8-K · Current report | Sep 29, 2025 | Current report | SEC |
| 8-K · Current report | Sep 25, 2025 | Material contract | SEC |
| S-1 · Registration statement | Aug 29, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 29, 2025 | Material contract | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 21, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 19, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 30, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 30, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jul 29, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jul 29, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 1, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Jun 6, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 6, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 15, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | May 14, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 12, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 9, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 6, 2025 | Offer document | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 16, 2025 | Results | SEC |
| 10-K · Annual report | Apr 15, 2025 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 16, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 12, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 22, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 19, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| NT 10-Q · Late filing notice | Nov 15, 2024 | Explanation request | SEC |
| 8-K · Current report | Nov 14, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Nov 8, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 425 | Oct 15, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 15, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Oct 9, 2024 | Other filings | SEC |
| S-4/A · Registration statement, amended | Oct 9, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 4, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Sep 30, 2024 | Other filings | SEC |
| S-4/A · Registration statement, amended | Sep 30, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 18, 2024 | Management or board change | SEC |
| 424B5 · Prospectus | Sep 16, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 16, 2024 | Other filings | SEC |
| S-4 · Registration statement | Sep 13, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 11, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 11, 2024 | Other filings | SEC |
| S-3 · Registration statement | Sep 6, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 6, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 23, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 19, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 19, 2024 | Results | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2024 | Explanation request | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2024 | Meeting outcome | SEC |
This page holds 200 of 748 filings. Open Filings
Cap table
Built by 6ix from Akari Therapeutics PLC’s releases
- Common shares
- 2,285,165
- Fully diluted
- 2,285,165
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,285,165 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,285,165 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Wendy DiCicco Other companies: EyePoint, Inc. (Board Member · Since at least Jul 15, 2019); SWK Holdings Corp (Director · Feb 15, 2022 – Dec 30, 2022 · Past); CannaPharmaRx Inc. (Director · Feb 27, 2015 – Feb 27, 2015 · Past); Coherent Corp. (Director · Aug 17, 2013 – Apr 28, 2017 · Past) | Interim CFO · Jan 1, 2024 – May 1, 2024 · Past |
| James R. Neal Other companies: Processa Pharmaceuticals, Inc. (Director · Since at least Jul 19, 2022); Monterey Bio Acquisition Corp (Director · Sep 30, 2021 – Sep 30, 2021 · Past); Palisade Bio, Inc. (Director · Apr 27, 2021 – Feb 9, 2024 · Past) | Director · Since at least Nov 14, 2024 |
| Michael Grissinger Other companies: Lipocine Inc. (Director · Since at least Aug 3, 2026); Aprea Therapeutics, Inc. (Director · Since at least May 16, 2022); Adicet Bio, Inc. (Director · Since at least Nov 5, 2018) | Director · Jan 1, 2024 – Jun 28, 2024 · Past |
| Rachelle Jacques Other companies: uniQure N.V. (Director · Since at least Oct 21, 2021); Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Jun 17, 2021); Viela Bio Inc (Director · Mar 15, 2021 – Mar 15, 2021 · Past) | Chief Executive Officer, Director · Jan 1, 2024 – Apr 26, 2024 · Past |
| Robert Bazemore Other companies: Nuvation Bio Inc. (Director · Since at least Sep 3, 2024); Ardelyx, Inc. (Director · Since at least Jun 14, 2024) | Director · Since at least Sep 17, 2024 |
| Donald A. Williams Other companies: Palisade Bio, Inc. (Director · Since at least Jun 10, 2026) | Director · Jan 1, 2024 – Jun 28, 2024 · Past |
| Hoyoung Huh Other companies: Pliant Therapeutics, Inc. (Director · Since at least Jun 16, 2022) | Chairman · Since at least Nov 14, 2024 |
| Abizer Gaslightwala | Director, President and CEO · Since at least Oct 16, 2026 |
| Amos Eiran | Director · Jan 1, 2015 – Jan 1, 2015 · Past |
| Kameel D. Farag | Interim Chief Financial Officer · Since at least Nov 5, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Pablo Jimenez | Chief Medical Officer · Jan 1, 2015 – Jan 1, 2015 · Past |
| Raymond Prudo-Chlebosz | Director · Since at least Dec 16, 2025 |
| Ray Prudo | Director · Since at least Nov 5, 2026 |
| Samir R. Patel | Director · Since at least Dec 16, 2025 |
| Sandip I. Patel | Director · Since at least Oct 16, 2026 |
| Satyajit Mitra | Executive Director, Head of Oncology · Since at least Oct 30, 2026 |
| Vatnak Vat-Ho | Chief Business Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Akari Therapeutics PLC.